Advertisement

Topics

FDA Approves New Therapy for IDH2m Relapsed/Refractory AML

16:42 EDT 1 Aug 2017 | Drug Discovery Development

The FDA granted approval for enasidenib (Idhifa) for adult patients with relapsed or refractory AML (R/R AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.
Staff Author: 
Topics: 

Original Article: FDA Approves New Therapy for IDH2m Relapsed/Refractory AML

NEXT ARTICLE

More From BioPortfolio on "FDA Approves New Therapy for IDH2m Relapsed/Refractory AML"

Quick Search
Advertisement
 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...